Radiolabeled TSPO Targeted Molecular Probe in Glioma

Exclusion Criteria

• •Individuals with a history of allergy to drugs with similar chemical or biological components to TSPO, a history of atopy, or currently suffering from allergic diseases.
• •Individuals currently participating in other drug clinical studies, or who have previously participated in any drug (excluding vitamins and minerals) clinical studies.
• •Individuals with other difficult-to-control clinical conditions, such as HIV infection, hepatitis C virus infection, active hepatitis B, other severe chronic infections, or serious mental, neurological, cardiovascular, respiratory, or other systemic diseases.
• •Red blood cell count (RBC) \< 4×10\^12/L, white blood cell count (WBC) \< 3×10\^9/L, hemoglobin \< 110 g/L, platelet count (PLT) \< 75×10\^9/L.
• •Significant liver and kidney function abnormalities, glomerular filtration rate (GFR) \< 50 ml/min.
• •Tumor burden involving more than 50% of the affected organ, or significant spinal cord compression.
• •Expected survival time less than six months, or having received chemotherapy within the past six months.
• •Individuals with severe acute comorbidities or severe refractory mental disorders.
• •Pregnant or breastfeeding women (pregnancy defined as a positive urine pregnancy test).
• •Individuals whose physical condition is unsuitable for radioactive examination.
• •Other circumstances deemed unsuitable for participation in the trial by the investigator.